What is a common initial management approach for mild sarcoidosis?

What is a common initial management approach for mild sarcoidosis?

• A. Observation with no treatment
• B. Immediate high-dose corticosteroids
• C. Immunotherapy with monoclonal antibodies
• D. Lung transplantation as first-line

Answer: (A)

For mild sarcoidosis, observation without treatment is a reasonable initial approach because many cases improve or even resolve on their own over time. The goal is to avoid exposing patients to the side effects of systemic therapy when the disease is not causing significant symptoms or organ damage. Corticosteroids are reserved for those with persistent symptoms, functional impairment, or involvement of critical organs (such as eyes, heart, or nervous system) or for hypercalcemia. In such cases, steroids can help reduce inflammation and prevent progression, but they carry meaningful side effects, so their use is weighed carefully. Immunotherapy with monoclonal antibodies is typically reserved for refractory or difficult-to-treat disease, not as first-line for mild cases. Lung transplantation is only considered for end-stage, irreversible pulmonary disease.

For mild sarcoidosis, observation without treatment is a reasonable initial approach because many cases improve or even resolve on their own over time. The goal is to avoid exposing patients to the side effects of systemic therapy when the disease is not causing significant symptoms or organ damage. Corticosteroids are reserved for those with persistent symptoms, functional impairment, or involvement of critical organs (such as eyes, heart, or nervous system) or for hypercalcemia. In such cases, steroids can help reduce inflammation and prevent progression, but they carry meaningful side effects, so their use is weighed carefully. Immunotherapy with monoclonal antibodies is typically reserved for refractory or difficult-to-treat disease, not as first-line for mild cases. Lung transplantation is only considered for end-stage, irreversible pulmonary disease.